3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
23
Lymphoma, Non-Hodgkin
22
Lymphoma, Large B-Cell, Diffuse
16
Hodgkin Disease
16
Lymphoma, Mantle-Cell
13
Lymphoma, Follicular
13
Burkitt Lymphoma
9
Multiple Myeloma
7
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, B-Cell
6
Glioblastoma
6
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Leukemia
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, T-Cell
4
Gliosarcoma
4
Glioma
4
Recurrence
3
Neoplasms, Plasma Cell
3
Neoplasms
3
Leukemia, Myeloid, Acute
3
Congenital Abnormalities
3
Astrocytoma
3
Waldenstrom Macroglobulinemia
2
Primary Myelofibrosis
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Myeloproliferative Disorders
2
Myelodysplastic-Myeloproliferative Diseases
2
Myelodysplastic Syndromes
2
Interventions
blinatumomab
4
Rituximab
4
Cyclophosphamide
3
ponatinib
2
Vorinostat
2
Vincristine
2
Prednisone
2
Ifosfamide
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bortezomib
2
tetulomab tetraxetan lu-177
1
pembrolizumab
1
pegaspargase
1
ibrutinib
1
ibritumomab tiuxetan
1
durvalumab
1
cobomarsen
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Methotrexate
1
Melphalan
1
Lutetium
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Hsp90 inhibitor KU757
1
Dexamethasone
1
Daunorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Immunoproliferative Disorders
×
Carmustine
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts